CASI PHARMACEUTICALS, INC. (NASDAQ:CASI) Files An 8-K Other EventsItem 8.01. Other Information.
On September 7, 2017, the CASI Pharmaceuticals Inc. (the “Company) issued a press release that provides an update on the Company’s development pipeline. A copy of the press release is attached hereto as Exhibit 99.1 and is incorporated herein by reference.
Item 9.01. Financial Statements and Exhibits.
(d) Exhibits
|
Exhibit Number |
Description |
| 99.1 | Press release dated September 7, 2017 |
CASI Pharmaceuticals, Inc. ExhibitEX-99.1 2 v474790_ex99-1.htm EXHIBIT 99.1 Exhibit 99.1 www.casipharmaceuticals.com FOR IMMEDIATE RELEASE: CASI PROVIDES PIPELINE DEVELOPMENT UPDATE ROCKVILLE,…To view the full exhibit click here
About CASI PHARMACEUTICALS, INC. (NASDAQ:CASI)
CASI Pharmaceuticals, Inc. is a biopharmaceutical company. The Company is focused on the acquisition, development and commercialization of therapeutics for cancer and other medical needs. It operates through the development of targeted therapeutics for the treatment of cancer segment. Its product pipeline includes internal development of its lead drug candidate, ENMD-2076; MARQIBO, ZEVALIN and EVOMELA, and early-stage candidates in preclinical development. Its ENMD-2076 is an orally active, Aurora A/angiogenic kinase inhibitor with a kinase selectivity profile and multiple mechanisms of action. Its Marqibo is a sphingomyelin/cholesterol liposome-encapsulated, formulation of vincristine sulfate. Its ZEVALIN (ibritumomab tiuxetan) injection for intravenous use is a CD20-directed radiotherapeutic antibody. Its EVOMELA is an intravenous formulation of melphalan being investigated by Spectrum in the multiple myeloma transplant setting. Its pipeline also includes 2ME2 (2-methoxyestradial).
